It suggests that FA/p-CA ameliorate NAFLD by inhibiting free fatty acid uptake via the HDAC1/PPARG axis, which may provide potential dietary supplements and drugs for prevention of NAFLD. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.